| USD ($) $ in Millions | LTM | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Provided by (Used in) Operating Activities | ||||||||||||||||||
Net earnings (loss) - Consumer products | - | - | - | - | ||||||||||||||
Net earnings (loss) - Financial services | - | - | - | - | ||||||||||||||
Earnings from discontinued operations, net of income taxes | - | - | - | - | ||||||||||||||
Net earnings (losses) | 7,973 | 6,947 | 11,264 | 8,130 | ||||||||||||||
Impact of earnings from discontinued operations, net of income taxes | - | - | - | - | ||||||||||||||
Adjustments to reconcile net earnings to operating cash flows: | ||||||||||||||||||
Consumer products | ||||||||||||||||||
Depreciation and amortization | 236 | 266 | 286 | 272 | ||||||||||||||
Deferred income tax provision (benefit) | (316) | (316) | 951 | (230) | ||||||||||||||
Unrecognized tax benefit | - | 303 | (1,128) | 1,111 | ||||||||||||||
Fair value adjustment for NJOY Transaction contingent payments, net of cash paid | 0 | 25 | - | - | ||||||||||||||
(Income) losses from investments in equity securities | (464) | (510) | (652) | (243) | ||||||||||||||
Gain on the sale of IQOS System commercialization rights | - | 0 | (2,700) | - | ||||||||||||||
(Income) losses from investments in equity securities | - | - | - | - | ||||||||||||||
Earnings from equity investments | - | - | - | - | ||||||||||||||
Loss on ABI/SABMiller business combination | - | - | - | - | ||||||||||||||
Dividends from ABI | 213 | 208 | 139 | 163 | ||||||||||||||
Impairment of goodwill | 285 | 1,158 | - | - | ||||||||||||||
Asset impairment and exit costs, net of cash paid | 975 | 960 | - | - | ||||||||||||||
Asset impairment and exit costs | - | - | 389 | - | ||||||||||||||
Loss on Cronos-related financial instruments | - | - | - | 0 | ||||||||||||||
Impairment of JUUL equity securities | - | - | - | - | ||||||||||||||
Escrow bond for the Engle tobacco case | - | - | - | - | ||||||||||||||
Asset impairment and exit costs, net of cash paid | - | - | - | - | ||||||||||||||
IRS payment related to LILO and SILO transactions | - | - | - | - | ||||||||||||||
Gain on sale of corporate headquarters building | - | - | - | - | ||||||||||||||
Loss on early extinguishment of debt | - | - | - | 0 | ||||||||||||||
PMCC leveraged lease charges | - | - | - | - | ||||||||||||||
IRS payment related to the Closing Agreement | - | - | - | - | ||||||||||||||
Cash effects of changes: | ||||||||||||||||||
Receivables | (67) | (86) | (106) | 6 | ||||||||||||||
Inventories | (102) | (27) | 102 | (15) | ||||||||||||||
Accounts payable | 110 | 34 | 116 | 38 | ||||||||||||||
Income taxes | 608 | 690 | 798 | 6 | ||||||||||||||
Accrued liabilities and other current assets | (525) | (359) | (550) | 280 | ||||||||||||||
Accrued liabilities and other current assets | - | - | - | - | ||||||||||||||
Accrued settlement charges | 71 | (176) | (209) | (362) | ||||||||||||||
Pension plan contributions | (15) | (16) | (18) | (20) | ||||||||||||||
Pension and postretirement, net | (52) | (78) | (107) | (136) | ||||||||||||||
Other, net | 175 | 267 | 178 | 287 | ||||||||||||||
Pension provisions and postretirement, net | - | - | - | - | ||||||||||||||
Other, net | - | - | - | - | ||||||||||||||
Financial services | ||||||||||||||||||
PMCC leveraged lease charges | - | - | - | - | ||||||||||||||
PMCC Leveraged Lease Charge | - | - | - | - | ||||||||||||||
Deferred income tax benefit | - | - | - | - | ||||||||||||||
Net (decrease) increase to allowance for losses | - | - | - | - | ||||||||||||||
Other liabilities - income taxes | - | - | - | - | ||||||||||||||
Other | - | - | - | - | ||||||||||||||
Net cash provided by operating activities, discontinued operations | - | - | - | - | ||||||||||||||
Net cash provided by (used in) operating activities | 9,408 | 9,290 | 8,753 | 9,287 | ||||||||||||||
Net Cash Provided by (Used in) Operating Activities | - | - | - | - | ||||||||||||||
Cash Provided by (Used in) Investing Activities | ||||||||||||||||||
Consumer products | ||||||||||||||||||
Capital expenditures | (296) | (216) | (142) | (196) | ||||||||||||||
Investment in JUUL | - | - | - | - | ||||||||||||||
Financial services | ||||||||||||||||||
Proceeds from finance assets | - | - | - | - | ||||||||||||||
Proceeds from the ABI Transaction | - | 0 | 2,353 | - | ||||||||||||||
Proceeds from the sale of IQOS System commercialization rights | 0 | 0 | 0 | 1,700 | ||||||||||||||
Acquisitions of businesses and assets | - | - | - | - | ||||||||||||||
Investment in Cronos | - | - | - | - | ||||||||||||||
Proceeds from the Ste. Michelle Transaction, net of cash transferred | - | - | - | 0 | ||||||||||||||
Acquisition of NJOY, net of cash acquired | 0 | 0 | 0 | (2,751) | ||||||||||||||
Purchase of AB InBev ordinary shares | - | - | - | - | ||||||||||||||
Payment for derivative financial instruments | - | - | - | - | ||||||||||||||
Proceeds from derivative financial instruments | - | - | - | - | ||||||||||||||
Payment for derivative financial instrument | - | - | - | - | ||||||||||||||
Proceeds from sale of corporate headquarters building | - | - | - | - | ||||||||||||||
Acquisition of John Middleton Co., net of acquired cash | - | - | - | - | ||||||||||||||
Other, net | (132) | (125) | (36) | (36) | ||||||||||||||
Investments in finance assets | - | - | - | - | ||||||||||||||
Net cash used in investing activities, discontinued operations | - | - | - | - | ||||||||||||||
Net cash provided by (used in) investing activities | (428) | (341) | 2,175 | (1,283) | ||||||||||||||
Net cash provided by (used in) investing activities | - | - | - | - | ||||||||||||||
Cash Provided by (Used in) Financing Activities | ||||||||||||||||||
Proceeds from short-term borrowings | 0 | 0 | 0 | 2,000 | ||||||||||||||
Repayment of short-term borrowings | 0 | 0 | 0 | (2,000) | ||||||||||||||
Consumer products | ||||||||||||||||||
Net (repayment) issuance of short-term borrowings | - | - | - | - | ||||||||||||||
Long-term debt issued | 995 | 1,992 | 0 | 998 | ||||||||||||||
Long-term debt repaid | (1,069) | (1,607) | (1,121) | (1,566) | ||||||||||||||
Financial services | ||||||||||||||||||
Debt repaid | - | - | - | - | ||||||||||||||
Repurchases of common stock | (735) | (1,000) | (3,400) | (1,000) | ||||||||||||||
Dividends paid on common stock | (7,062) | (6,960) | (6,845) | (6,779) | ||||||||||||||
Issuances of common stock | - | - | - | - | ||||||||||||||
Kraft Foods Inc. dividends paid to Altria Group, Inc. | - | - | - | - | ||||||||||||||
Philip Morris International Inc. dividends paid to Altria Group, Inc. | - | - | - | - | ||||||||||||||
Financing fees and debt issuance costs | - | - | - | - | ||||||||||||||
Premiums and fees related to early extinguishment of debt | - | - | - | 0 | ||||||||||||||
Tender and consent fees related to the early extinguishment of debt | - | - | - | - | ||||||||||||||
Changes in amounts due to/from Philip Morris International Inc. | - | - | - | - | ||||||||||||||
Other, net | (39) | (40) | (125) | (27) | ||||||||||||||
Net cash used in financing activities, discontinued operations | - | - | - | - | ||||||||||||||
Net cash provided by (used in) financing activities | (7,910) | (7,615) | (11,491) | (8,374) | ||||||||||||||
Cash, cash equivalents and restricted cash: | ||||||||||||||||||
Net cash used in financing activities | - | - | - | - | ||||||||||||||
Effect of exchange rate changes on cash and cash equivalents: | ||||||||||||||||||
Discontinued operations | - | - | - | - | ||||||||||||||
Cash, cash equivalents and restricted cash: | ||||||||||||||||||
Increase (decrease) | 1,070 | 1,334 | (563) | (370) | ||||||||||||||
Supplemental cash flow information: | ||||||||||||||||||
Cash paid: Interest | 1,114 | 1,114 | 1,113 | 1,116 | ||||||||||||||
- Financial services | - | - | - | - | ||||||||||||||
Cash Paid: Income taxes | 1,695 | 1,695 | 1,802 | 1,890 | ||||||||||||||
Non-cash investing activities: | ||||||||||||||||||
Deferred proceeds from the sale of IQOS System commercialization rights | - | - | $ 0 | $ 0 |